Category: clinical trial

0

Real-World Evidence (RWE) Studies in APAC: Regulatory Pathways, Site Qualification, and Key Considerations Before Protocol Finalization

Sponsors running real-world evidence studies in APAC face a different planning challenge from those running interventional trials. The study design is not the primary source of complexity. The data infrastructure is. So is each market’s regulatory acceptance posture and the site capability to manage observational methodology. Sponsors who treat the APAC region as a single […]

Read More →
0

Five Things Sponsors Assume About APAC Regulatory Timelines That Turn Out to Be Wrong: A Market-by-Market Reality Check

Most sponsors enter APAC planning with a set of mental shortcuts. Singapore is the gateway. Japan is too slow. India’s 90-day rule means India is fast. Ethics approval runs in parallel and takes care of itself. These assumptions are reasonable on the surface. However, each one creates timeline risk that compounds across markets. The gap […]

Read More →
0

ICH M14 and Non-Interventional Studies Using Real-World Data: What Asia-Pacific Sponsors Need to Prepare

If you run post-marketing safety studies on real-world data, you have worked without a single harmonised planning standard. Each region asked for something slightly different. For example, a protocol written for one regulator often needed rebuilding for the next. As a result, a sponsor with commitments in three markets could end up running three studies […]

Read More →
0

India’s New Drugs and Clinical Trials (NDCT) Amendment Rules 2026: What Clinical Trial and BA/BE Sponsors Need to Know

You are planning a BA/BE study in India. Your regulatory timeline budgets 90 working days for CDSCO to review your test licence application. In January 2026, India’s Ministry of Health and Family Welfare changed that. They notified the New Drugs and Clinical Trials (Amendment) Rules, 2026 via Gazette Notification G.S.R. 46(E). The new rules cut […]

Read More →
0

Nutraceutical Clinical Trial Design: Why Studies Miss Their Endpoints

Your study ran. The product may well have worked. However, the primary endpoint was not met. The sample may have been too small. Or the measurement was inconsistent across sites. Or the effect size assumed in the power calculation was borrowed from a pharmaceutical dose with no relation to your formulation. The study is now […]

Read More →
0

Autoimmune Clinical Trials APAC: Protocol Assumptions That Slow Your Study

Your Phase II rheumatoid arthritis study is built on a protocol that worked in Europe. The comparator arm reflects European standard of care. The baseline disease activity thresholds come from US trial precedent. The site list was built from academic centres with strong track records in Western trials. You are now taking this protocol to […]

Read More →
0

Full Service CRO APAC: A Sponsor’s Guide to Phase II to IV Clinical Trial Management

You are planning a Phase II oncology study across three APAC markets. The protocol is close to final. Now comes the part most sponsors underestimate: selecting a CRO model that gives you execution control without building infrastructure you do not have. A full service CRO APAC engagement hands you one accountable partner across every function, […]

Read More →
0

Writing a Clinical Study Report in Line with ICH E3: Structure, Common Deficiencies, and What APAC Regulators Expect

A sponsor completes a Phase II oncology trial across three APAC markets. The data is clean, the efficacy signal is real, and the team followed the statistical analysis plan. The clinical study report takes eight weeks to draft. Six weeks after submission, the regulatory authority returns a deficiency notice. Not because the trial failed, but […]

Read More →
0

Publishing Clinical Trial Results: A Sponsor’s Guide to Manuscript Writing and Journal Submission

A sponsor completes a Phase III trial with a positive primary endpoint. The database is locked, the clinical study report is filed, and the regulatory submission is in. Manuscript writing comes next. Six months later, two journals have rejected the draft. It now sits in a third journal’s review queue, and the lead author has […]

Read More →
0

Singapore vs. Malaysia for Phase II Clinical Trials: Regulatory Speed, Site Quality, and Cost

Singapore and Malaysia are the two most-cited APAC markets for sponsors planning Phase II clinical trials outside Japan, India, and Australia. Both have strong regulatory frameworks, experienced investigator pools, and GCP-compliant site infrastructure. Because they are close enough in quality to require a deliberate choice, and different enough in cost and timelines for that choice […]

Read More →